Skip to main content
Home Friends of Cancer Research

Main navigation

  • 25th Anniversary
  • About
    • About Friends
    • Celebrating 25 Years
    • Team
    • Board of Directors
    • Financials & Policies
  • Science & Policy
    • About Breakthrough Therapies
    • Search Breakthrough Therapies
    • Data Driven Insights
    • ctDNA
    • HRD Harmonization Project
    • Cell Therapies
    • Clinical Trial Eligibility Criteria
    • Tumor Mutational Burden (TMB)
    • COVID-19
    • Real-World Evidence
    • Rx Drug Labeling
    • Centers of Excellence
    • Lung-MAP
    • Tolerability in Cancer Clinical Trials
  • News
    • In The News
    • Blog: Engaging Innovation
    • Press Releases
  • Events
    • Upcoming Events
    • Event Archive
    • Annual Meeting
    • Friends-Alexandria Blueprint Forum
  • Patients
    • Prevention, Detection, & Diagnosis
    • Clinical Trials
    • Find a Cancer Center
    • Glossary of Terms
  • Education
  • Publications
  • Donate
 

Cancer and Drug Development Terms

A

Accelerated Approval

Advisory Committees

B

Biologics License Applications (BLAs)

Biomarkers

Breakthrough Therapy

C

Cancer

CBER

Clinical Benefit

Clinical Trials

Clinical Trial Endpoints

Companion Diagnostics

Comparative Effectiveness

D

Drug Safety

E

Expedited Review Programs

  • Priority Review
  • Fast Track
  • Breakthrough Therapy
  • Accelerated Approval

F

Fast Track

FDA 

First-line Therapy

G

Generic Drugs

Genetic Medicine

I

Immunotherapy

Investigational New Drug Application (IND)

L

Label

Lung-MAP

M

Market Exclusivity

Master Protocol

N

National Institutes of Health (NIH)

National Cancer Institute (NCI)

New Drug Applications (NDAs)

Next Generation Sequencing (NGS)

O

Off-Label Use

Oncologic Drugs Advisory Committee (ODAC)

Orphan Drugs

P

Patents

PCORI

PDUFA

Personalized Medicine

Pivotal Trial

Placebo

Post-Market Clinical Trials

Priority Review

R

Randomized Clinical Trials

S

Second-Line Therapy

Single-Arm Clinical Trials

Standard of Care

T

Target Population

Targeted Therapies

Toxicity

Trial Design 

U

Unmet Medical Need

User Fees

Home

1800 M Street NW, Suite 1050 South, Washington, DC 20036 - Phone: (202) 944-6700

Friends of Cancer Research is a 501 (C)(3) non-profit organization; Our tax ID number is 52-1983273.

Footer Menu 1

  • About
  • Careers
  • Contact
  • Donate
  • Privacy Policy

Footer Menu 2

  • Policy on Corporate Partnerships
  • Terms & Conditions

© Copyright 2020 Friends of Cancer Research. All rights reserved.

Social menu footer

  • Linkedin
  • Twitter
  • Youtube